{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:33:18Z","timestamp":1781627598988,"version":"3.54.5"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010663","name":"h2020 european research council","doi-asserted-by":"publisher","award":["779312"],"award-info":[{"award-number":["779312"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007480","name":"Universidad de Castilla la Mancha","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007480","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiple sclerosis imposes a heavy burden on the person who suffers from it and on the relatives, due to the caregiving load involved. The objective was to analyse whether the inclusion of social costs in economic evaluations of multiple sclerosis-related interventions changed results and\/or conclusions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic review was launched using Medline and the Cost-Effectiveness Analysis Registry of Tufts University (2000\u20132019). Included studies should: (1) be an original study published in a scientific journal, (2) be an economic evaluation of any multiple sclerosis-related intervention, (3) include productivity losses and\/or informal care costs (social costs), (4) be written in English, (5) use quality-adjusted life years as outcome, and (6) separate the results according to the perspective applied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-nine articles were selected, resulting in 67 economic evaluation estimations. Social costs were included in 47% of the studies. Productivity losses were assessed in 90% of the estimations (the human capital approach was the most frequently used method), whereas informal care costs were included in nearly two-thirds of the estimations (applying the opportunity and the replacement-cost methods equally). The inclusion of social costs modified the figures for incremental costs in 15 estimations, leading to a change in the conclusions in 10 estimations, 6 of them changing from not recommended from the healthcare perspective to implemented from the societal perspective. The inclusion of social costs also altered the results from cost-effective to dominant in five additional estimations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The inclusion of social costs affected the results\/conclusions in multiple sclerosis-related interventions, helping to identify the most appropriate interventions for reducing its economic burden from a broader perspective.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10198-022-01471-9","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T20:08:43Z","timestamp":1653077323000},"page":"247-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6146-068X","authenticated-orcid":false,"given":"B.","family":"Rodr\u00edguez-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Daugbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7224-2189","authenticated-orcid":false,"given":"L. M.","family":"Pe\u00f1a-Longobardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8997-0307","authenticated-orcid":false,"given":"J.","family":"Oliva-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7311-2615","authenticated-orcid":false,"given":"I.","family":"Aranda-Reneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4633-9195","authenticated-orcid":false,"given":"A.","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"L\u00f3pez-Bastida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"1471_CR1","first-page":"1503","volume":"12","author":"JM Polimeni","year":"2013","unstructured":"Polimeni, J.M., Vichansavakul, K., Iorgulescu, R.I., Chandrasekara, R.: Why perspective matters in health outcomes research analyses. Int. Bus. Econ. Res. J. 12, 1503\u20131512 (2013)","journal-title":"Int. Bus. Econ. Res. J."},{"key":"1471_CR2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40273-018-0730-6","volume":"37","author":"W Brouwer","year":"2019","unstructured":"Brouwer, W.: The inclusion of spillover effects in economic evaluations: Not an optional extra. Pharmacoeconomics 37, 451\u2013456 (2019). https:\/\/doi.org\/10.1007\/s40273-018-0730-6","journal-title":"Pharmacoeconomics"},{"key":"1471_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1017\/S026646232000001X","volume":"36","author":"RMWA Drost","year":"2020","unstructured":"Drost, R.M.W.A., Paulus, A.T.G., Evers, S.M.A.A.: Five pillars for societal perspective. Int. J. Technol. Assess. Health. Care. 36, 72\u201374 (2020)","journal-title":"Int. J. Technol. Assess. Health. Care."},{"key":"1471_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10198-009-0173-2","volume":"10","author":"B J\u00f6nsson","year":"2009","unstructured":"J\u00f6nsson, B.: Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur. J. Health. Econ. 10, 357\u2013359 (2009)","journal-title":"Eur. J. Health. Econ."},{"key":"1471_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4321\/S1135-57272015000100002","volume":"89","author":"J Oliva","year":"2015","unstructured":"Oliva, J., Brosa, M., Esp\u00edn, J., Figueras, M., Trapero, M., Key4Value-Grupo: Controversial issues in economic evaluation (I): Perspective and costs of health care interventions. Rev. Esp. Salud. Publica 89, 5\u201314 (2015). https:\/\/doi.org\/10.4321\/S1135-57272015000100002","journal-title":"Rev. Esp. Salud. Publica"},{"key":"1471_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40273-019-00768-7","volume":"37","author":"E Wittenberg","year":"2019","unstructured":"Wittenberg, E., James, L.P., Prosser, L.A.: Spillover effects on caregivers\u2019 and family members\u2019 utility: A systematic review of the literature. Pharmacoeconomics 37, 475\u2013499 (2019). https:\/\/doi.org\/10.1007\/s40273-019-00768-7","journal-title":"Pharmacoeconomics"},{"key":"1471_CR7","doi-asserted-by":"publisher","DOI":"10.15586\/codon.multiplesclerosis.2017","volume-title":"Multiple sclerosis: Perspectives in treatment and pathogenesis","author":"IS Zagon","year":"2017","unstructured":"Zagon, I.S., McLaughlin, P.J.: Multiple sclerosis: Perspectives in treatment and pathogenesis. Codon PublicationsBrisbane, Australia (2017)"},{"key":"1471_CR8","first-page":"948","volume":"40","author":"BK Tsang","year":"2011","unstructured":"Tsang, B.K., Macdonell, R.: Multiple sclerosis- diagnosis, management and prognosis. Aust. Fam. Physician. 40, 948\u2013955 (2011)","journal-title":"Aust. Fam. Physician."},{"key":"1471_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.apjtb.2016.03.009","volume":"6","author":"KMM Koriem","year":"2016","unstructured":"Koriem, K.M.M.: Multiple sclerosis: New insights and trends. Asian. Pacific. J. Trop. Biomed. 6, 429\u2013440 (2016). https:\/\/doi.org\/10.1016\/j.apjtb.2016.03.009","journal-title":"Asian. Pacific. J. Trop. Biomed."},{"key":"1471_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s1474-4422(05)70071-5","volume":"4","author":"D Miller","year":"2005","unstructured":"Miller, D., Barkhof, F., Montalban, X., Thompson, A., Filippi, M.: Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet. Neurol. 4, 281\u2013288 (2005). https:\/\/doi.org\/10.1016\/s1474-4422(05)70071-5","journal-title":"Lancet. Neurol."},{"key":"1471_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/jnnp-2012-303996","volume":"84","author":"KE Harding","year":"2013","unstructured":"Harding, K.E., Liang, K., Cossburn, M.D., Ingram, G., Hirst, C.L., Pickersgill, T.P., Te Water Naude, J., Wardle, M., Ben-Shlomo, Y., Robertson, N.P.: Long-term outcome of paediatric-onset multiple sclerosis: a population-based study. J. Neurol. Neurosurg. Psychiatry. 84, 141\u2013147 (2013). https:\/\/doi.org\/10.1136\/jnnp-2012-303996","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"1471_CR12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt, G., Thompson, A., Berg, J., Gannedahl, M., Eriksson, J., Group, M.S., Platform, E.M.S.: New insights into the burden and costs of multiple sclerosis in Europe. Multe. Scler. J. 23, 1123\u20131136 (2017)","journal-title":"Multe. Scler. J."},{"key":"1471_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1177\/1352458519831213","volume":"26","author":"AJ Palmer","year":"2020","unstructured":"Palmer, A.J., van der Mei, I., Taylor, B.V., Clarke, P.M., Simpson, S., Jr., Ahmad, H.: Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia. Mult. Scler. 26, 411\u2013420 (2020). https:\/\/doi.org\/10.1177\/1352458519831213","journal-title":"Mult. Scler."},{"key":"1471_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/jnnp-2011-300616","volume":"83","author":"E Kingwell","year":"2012","unstructured":"Kingwell, E., van der Kop, M., Zhao, Y., Shirani, A., Zhu, F., Oger, J., Tremlett, H.: Relative mortality and survival in multiple sclerosis: findings from British Columbia. Canada. J. Neurol. Neurosurg. Psychiatry. 83, 61\u201366 (2012). https:\/\/doi.org\/10.1136\/jnnp-2011-300616","journal-title":"Canada. J. Neurol. Neurosurg. Psychiatry."},{"key":"1471_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1212\/WNL.0b013e31829a3388","volume":"81","author":"A Scalfari","year":"2013","unstructured":"Scalfari, A., Knappertz, V., Cutter, G., Goodin, D.S., Ashton, R., Ebers, G.C.: Mortality in patients with multiple sclerosis. Neurology 81, 184\u2013192 (2013). https:\/\/doi.org\/10.1212\/WNL.0b013e31829a3388","journal-title":"Neurology"},{"key":"1471_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1212\/wnl.0000000000001718","volume":"85","author":"RA Marrie","year":"2015","unstructured":"Marrie, R.A., Elliott, L., Marriott, J., Cossoy, M., Blanchard, J., Leung, S., Yu, N.: Effect of comorbidity on mortality in multiple sclerosis. Neurology 85, 240\u2013247 (2015). https:\/\/doi.org\/10.1212\/wnl.0000000000001718","journal-title":"Neurology"},{"key":"1471_CR17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1136\/jnnp-2016-315238","volume":"88","author":"HMB Lunde","year":"2017","unstructured":"Lunde, H.M.B., Assmus, J., Myhr, K.M., B\u00f8, L., Grytten, N.: Survival and cause of death in multiple sclerosis: A 60-year longitudinal population study. J. Neurol. Neurosurg. Psychiatry. 88, 621\u2013625 (2017). https:\/\/doi.org\/10.1136\/jnnp-2016-315238","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"1471_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.neurol.2015.10.006","volume":"172","author":"E Leray","year":"2016","unstructured":"Leray, E., Moreau, T., Fromont, A., Edan, G.: Epidemiology of multiple sclerosis. Rev. Neurol. (Paris). 172, 3\u201313 (2016). https:\/\/doi.org\/10.1016\/j.neurol.2015.10.006","journal-title":"Rev. Neurol. (Paris)."},{"key":"1471_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.msard.2019.01.045","volume":"30","author":"FBS Briggs","year":"2019","unstructured":"Briggs, F.B.S., Thompson, N.R., Conway, D.S.: Prognostic factors of disability in relapsing remitting multiple sclerosis. Mult. Scler. Relat. Disord. 30, 9\u201316 (2019)","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1471_CR20","doi-asserted-by":"publisher","first-page":"e2764","DOI":"10.1212\/WNL.0000000000007647","volume":"92","author":"KA McKay","year":"2019","unstructured":"McKay, K.A., Hillert, J., Manouchehrinia, A.: Long-term disability progression of pediatric-onset multiple sclerosis. Neurology 92, e2764\u2013e2773 (2019)","journal-title":"Neurology"},{"key":"1471_CR21","doi-asserted-by":"publisher","first-page":"e0159129","DOI":"10.1371\/journal.pone.0159129","volume":"11","author":"O Ernstsson","year":"2016","unstructured":"Ernstsson, O., Gyllensten, H., Alexanderson, K., Tingh\u00f6g, P., Friberg, E., Norlund, A.: Cost of illness of multiple sclerosis-a systematic review. PLoS. One 11, e0159129 (2016)","journal-title":"PLoS. One"},{"key":"1471_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-020-01043-5","author":"R Maguire","year":"2020","unstructured":"Maguire, R., Maguire, P.: Caregiver burden in multiple sclerosis: Recent trends and future directions. Curr. Neurol. Neurosci. Rep (2020). https:\/\/doi.org\/10.1007\/s11910-020-01043-5","journal-title":"Curr. Neurol. Neurosci. Rep"},{"key":"1471_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jns.2013.04.007","volume":"330","author":"H Paris\u00e9","year":"2013","unstructured":"Paris\u00e9, H., Lalibert\u00e9, F., Lefebvre, P., Duh, M.S., Kim, E., Agashivala, N., Abouzaid, S., Weinstock-Guttman, B.: Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. J. Neurol. Sci. 330, 71\u201377 (2013)","journal-title":"J. Neurol. Sci."},{"key":"1471_CR24","first-page":"205521732090172","volume":"6","author":"RS Nicholas","year":"2020","unstructured":"Nicholas, R.S., Heaven, M.L., Middleton, R.M., Chevli, M., Pulikottil-Jacob, R., Jones, K.H., Ford, D.V.: Personal and societal costs of multiple sclerosis in the UK: A population-based MS Registry study. Mult. Scler. J-Exp, Transl. Clin. 6, 2055217320901727 (2020)","journal-title":"Mult. Scler. J-Exp, Transl. Clin."},{"key":"1471_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-6907-x","author":"JM Garc\u00eda-Dom\u00ednguez","year":"2019","unstructured":"Garc\u00eda-Dom\u00ednguez, J.M., Maurino, J., Mart\u00ednez-Gin\u00e9s, M.L., Carmona, O., Caminero, A.B., Medrano, N., Ru\u00edz-Beato, E.: Economic burden of multiple sclerosis in a population with low physical disability. BMC. Public. Health (2019). https:\/\/doi.org\/10.1186\/s12889-019-6907-x","journal-title":"BMC. Public. Health"},{"key":"1471_CR26","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group p: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS. Med 6, e1000097 (2009)","journal-title":"PLoS. Med"},{"key":"1471_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/2152-2812.1114","volume":"3","author":"T Thorat","year":"2012","unstructured":"Thorat, T., Cangelosi, M., Neumann, P.J.: Skills of the trade: The tufts cost-effectiveness analysis registry. J. Benefit-Cost. Anal. 3, 1\u20139 (2012)","journal-title":"J. Benefit-Cost. Anal."},{"key":"1471_CR28","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1182\/blood-2014-07-592832","volume":"125","author":"CJ Saret","year":"2015","unstructured":"Saret, C.J., Winn, A.N., Shah, G., Parsons, S.K., Lin, P.J., Cohen, J.T., Neumann, P.J.: Value of innovation in hematologic malignancies: A systematic review of published cost-effectiveness analyses. Blood 125, 1866\u20131869 (2015). https:\/\/doi.org\/10.1182\/blood-2014-07-592832","journal-title":"Blood"},{"key":"1471_CR29","doi-asserted-by":"publisher","unstructured":"OECD\/Eurostat\/WHO: A System of Health Accounts 2011: Revised edition. OECD Publishing, Paris (2017). https:\/\/doi.org\/10.1787\/9789264270985-en","DOI":"10.1787\/9789264270985-en"},{"key":"1471_CR30","doi-asserted-by":"publisher","DOI":"10.3310\/hta19120","author":"S Ball","year":"2015","unstructured":"Ball, S., Vickery, J., Hobart, J., Wright, D., Green, C., Shearer, J., Nunn, A., Cano, M.G., MacManus, D., Miller, D., Mallik, S., Zajicek, J.: The cannabinoid use in progressive inflammatory brain disease (CUPID) trial: A randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health. Technol. Assess (2015). https:\/\/doi.org\/10.3310\/hta19120","journal-title":"Health. Technol. Assess"},{"key":"1471_CR31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.18553\/jmcp.2007.13.3.245","volume":"13","author":"C Bell","year":"2007","unstructured":"Bell, C., Graham, J., Earnshaw, S., Oleen-Burkey, M., Castelli-Haley, J., Johnson, K.: Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: A Markov model based on long-term clinical data. J. Manag. Care. Pharm. 13, 245\u2013261 (2007). https:\/\/doi.org\/10.18553\/jmcp.2007.13.3.245","journal-title":"J. Manag. Care. Pharm."},{"key":"1471_CR32","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1177\/1352458515576261","volume":"21","author":"A Bogosian","year":"2015","unstructured":"Bogosian, A., Chadwick, P., Windgassen, S., Norton, S., McCrone, P., Mosweu, I., Silber, E., Moss-Morris, R.: Distress improves after mindfulness training for progressive MS: A pilot randomised trial. Mult. Scler. 21, 1184\u20131194 (2015). https:\/\/doi.org\/10.1177\/1352458515576261","journal-title":"Mult. Scler."},{"key":"1471_CR33","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.clinthera.2012.03.004","volume":"34","author":"JP Caloyeras","year":"2012","unstructured":"Caloyeras, J.P., Zhang, B., Wang, C., Eriksson, M., Fredrikson, S., Beckmann, K., Knappertz, V., Pohl, C., Hartung, H.P., Shah, D., Miller, J.D., Sandbrink, R., Lanius, V., Gondek, K., Russell, M.W.: Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis. Clin. Ther. 34, 1132\u20131144 (2012). https:\/\/doi.org\/10.1016\/j.clinthera.2012.03.004","journal-title":"Clin. Ther."},{"key":"1471_CR34","doi-asserted-by":"publisher","first-page":"e0150703","DOI":"10.1371\/journal.pone.0150703","volume":"11","author":"J Chevalier","year":"2016","unstructured":"Chevalier, J., Chamoux, C., Hammes, F., Chicoye, A.: Cost-effectiveness of treatments for relapsing remitting multiple sclerosis: A French societal perspective. PLoS. ONE 11, e0150703 (2016). https:\/\/doi.org\/10.1371\/journal.pone.0150703","journal-title":"PLoS. ONE"},{"key":"1471_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2165\/11314900-000000000-0000010.1007\/bf03256144","volume":"7","author":"SR Earnshaw","year":"2009","unstructured":"Earnshaw, S.R., Graham, J., Oleen-Burkey, M., Castelli-Haley, J., Johnson, K.: Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl. Health. Econ. Health. Policy. 7, 91\u2013108 (2009). https:\/\/doi.org\/10.2165\/11314900-000000000-0000010.1007\/bf03256144","journal-title":"Appl. Health. Econ. Health. Policy."},{"key":"1471_CR36","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/13696998.2017.1357564","volume":"20","author":"MA Frasco","year":"2017","unstructured":"Frasco, M.A., Shih, T., Incerti, D., Diaz Espinosa, O., Vania, D.K., Thomas, N.: Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon beta-1a. J. Med. Econ. 20, 1074\u20131082 (2017). https:\/\/doi.org\/10.1080\/13696998.2017.1357564","journal-title":"J. Med. Econ."},{"key":"1471_CR37","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s12913-019-4264-1","volume":"19","author":"G Furneri","year":"2019","unstructured":"Furneri, G., Santoni, L., Ricella, C., Prosperini, L.: Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy. BMC. Health. Serv. Res. 19, 436 (2019). https:\/\/doi.org\/10.1186\/s12913-019-4264-1","journal-title":"BMC. Health. Serv. Res."},{"key":"1471_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2165\/00019053-200826070-00008","volume":"26","author":"R Gani","year":"2008","unstructured":"Gani, R., Giovannoni, G., Bates, D., Kemball, B., Hughes, S., Kerrigan, J.: Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 26, 617\u2013627 (2008). https:\/\/doi.org\/10.2165\/00019053-200826070-00008","journal-title":"Pharmacoeconomics"},{"key":"1471_CR39","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1586\/14737167.2016.1140574","volume":"16","author":"A Gras","year":"2016","unstructured":"Gras, A., Broughton, J.: A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis. Expert. Rev. Pharmacoecon. Outcomes. Res. 16, 771\u2013779 (2016). https:\/\/doi.org\/10.1586\/14737167.2016.1140574","journal-title":"Expert. Rev. Pharmacoecon. Outcomes. Res."},{"key":"1471_CR40","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1080\/13696998.2018.1461630","volume":"21","author":"R Hettle","year":"2018","unstructured":"Hettle, R., Harty, G., Wong, S.L.: Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. J. Med. Econ. 21, 676\u2013686 (2018). https:\/\/doi.org\/10.1080\/13696998.2018.1461630","journal-title":"J. Med. Econ."},{"key":"1471_CR41","first-page":"87","volume":"11","author":"A Imani","year":"2012","unstructured":"Imani, A., Golestani, M.: Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran. Iran. J. Neurol. 11, 87\u201390 (2012)","journal-title":"Iran. J. Neurol."},{"key":"1471_CR42","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1191\/1352458505ms1211oa","volume":"11","author":"M Iskedjian","year":"2005","unstructured":"Iskedjian, M., Walker, J.H., Gray, T., Vicente, C., Einarson, T.R., Gehshan, A.: Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event. Mult. Scler. 11, 542\u2013551 (2005). https:\/\/doi.org\/10.1191\/1352458505ms1211oa","journal-title":"Mult. Scler."},{"key":"1471_CR43","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2298\/vsp0907556j","volume":"66","author":"SM Jankovic","year":"2009","unstructured":"Jankovic, S.M., Kostic, M., Radosavljevic, M., Tesic, D., Stefanovic-Stoimenov, N., Stevanovic, I., Rakovic, S., Aleksic, J., Folic, M., Aleksic, A., Mihajlovic, I., Biorac, N., Borlja, J., Vuckovic, R.: Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition. Vojnosanit. Pregl. 66, 556\u2013562 (2009). https:\/\/doi.org\/10.2298\/vsp0907556j","journal-title":"Vojnosanit. Pregl."},{"key":"1471_CR44","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/1352458507086667","volume":"14","author":"G Kobelt","year":"2008","unstructured":"Kobelt, G., Berg, J., Lindgren, P., Jonsson, B., Stawiarz, L., Hillert, J.: Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult. Scler. 14, 679\u2013690 (2008). https:\/\/doi.org\/10.1177\/1352458507086667","journal-title":"Mult. Scler."},{"key":"1471_CR45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10198-002-0163-0","volume":"4","author":"G Kobelt","year":"2003","unstructured":"Kobelt, G., J\u00f6nsson, L., Fredrikson, S.: Cost-utility of interferon beta(1b) in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. Eur. J. Health. Econ. 4, 50\u201359 (2003)","journal-title":"Eur. J. Health. Econ."},{"key":"1471_CR46","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1017\/s0266462300102041","volume":"16","author":"G Kobelt","year":"2000","unstructured":"Kobelt, G., Jonsson, L., Henriksson, F., Fredrikson, S., Jonsson, B.: Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis. Int. J. Technol. Assess. Health. Care. 16, 768\u2013780 (2000). https:\/\/doi.org\/10.1017\/s0266462300102041","journal-title":"Int. J. Technol. Assess. Health. Care."},{"key":"1471_CR47","first-page":"127","volume":"18","author":"G Kobelt","year":"2002","unstructured":"Kobelt, G., Jonsson, L., Miltenburger, C., Jonsson, B.: Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data. Int. J. Technol. Assess. Health. Care. 18, 127\u2013138 (2002)","journal-title":"Int. J. Technol. Assess. Health. Care."},{"key":"1471_CR48","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/1352458509102771","volume":"15","author":"G Kobelt","year":"2009","unstructured":"Kobelt, G., Texier-Richard, B., Lindgren, P.: The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions. Mult. Scler. 15, 741\u2013751 (2009). https:\/\/doi.org\/10.1177\/1352458509102771","journal-title":"Mult. Scler."},{"key":"1471_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10072-009-0015-0","volume":"30","author":"C Lazzaro","year":"2009","unstructured":"Lazzaro, C., Bianchi, C., Peracino, L., Zacchetti, P., Uccelli, A.: Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b. Neurol. Sci. 30, 21\u201331 (2009). https:\/\/doi.org\/10.1007\/s10072-009-0015-0","journal-title":"Neurol. Sci."},{"key":"1471_CR50","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3111\/13696998.2015.1135805","volume":"19","author":"J Mauskopf","year":"2016","unstructured":"Mauskopf, J., Fay, M., Iyer, R., Sarda, S., Livingston, T.: Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. J. Med. Econ. 19, 432\u2013442 (2016). https:\/\/doi.org\/10.3111\/13696998.2015.1135805","journal-title":"J. Med. Econ."},{"key":"1471_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-017-0172-4","author":"I Mosweu","year":"2017","unstructured":"Mosweu, I., Moss-Morris, R., Dennison, L., Chalder, T., McCrone, P.: Cost-effectiveness of nurse-delivered cognitive behavioural therapy (CBT) compared to supportive listening (SL) for adjustment to multiple sclerosis. Health. Econ. Rev (2017). https:\/\/doi.org\/10.1186\/s13561-017-0172-4","journal-title":"Health. Econ. Rev"},{"key":"1471_CR52","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1212\/WNL.0b013e3182270402","volume":"77","author":"K Noyes","year":"2011","unstructured":"Noyes, K., Bajorska, A., Chappel, A., Schwid, S.R., Mehta, L.R., Weinstock-Guttman, B., Holloway, R.G., Dick, A.W.: Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology 77, 355\u2013363 (2011). https:\/\/doi.org\/10.1212\/WNL.0b013e3182270402","journal-title":"Neurology"},{"key":"1471_CR53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1046\/j.1524-4733.2002.51052.x","volume":"5","author":"MJ Nuijten","year":"2002","unstructured":"Nuijten, M.J., Hutton, J.: Cost-effectiveness analysis of interferon beta in multiple sclerosis: A Markov process analysis. Value. Health. 5, 44\u201354 (2002). https:\/\/doi.org\/10.1046\/j.1524-4733.2002.51052.x","journal-title":"Value. Health."},{"key":"1471_CR54","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.clinthera.2012.07.010","volume":"34","author":"F Pan","year":"2012","unstructured":"Pan, F., Goh, J.W., Cutter, G., Su, W., Pleimes, D., Wang, C.: Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States. Clin. Ther. 34, 1966\u20131976 (2012). https:\/\/doi.org\/10.1016\/j.clinthera.2012.07.010","journal-title":"Clin. Ther."},{"key":"1471_CR55","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.clinthera.2017.01.028","volume":"39","author":"E Soini","year":"2017","unstructured":"Soini, E., Joutseno, J., Sumelahti, M.L.: Cost-utility of first-line disease-modifying treatments for relapsing-remitting multiple sclerosis. Clin. Ther. 39, 537-557.e510 (2017). https:\/\/doi.org\/10.1016\/j.clinthera.2017.01.028","journal-title":"Clin. Ther."},{"key":"1471_CR56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/13696998.2018.1543189","volume":"22","author":"S Taheri","year":"2019","unstructured":"Taheri, S., Sahraian, M.A., Yousefi, N.: Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison. J. Med. Econ. 22, 71\u201384 (2019). https:\/\/doi.org\/10.1080\/13696998.2018.1543189","journal-title":"J. Med. Econ."},{"key":"1471_CR57","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458513515958","volume":"20","author":"J Tosh","year":"2014","unstructured":"Tosh, J., Dixon, S., Carter, A., Daley, A., Petty, J., Roalfe, A., Sharrack, B., Saxton, J.M.: Cost effectiveness of a pragmatic exercise intervention (EXIMS) for people with multiple sclerosis: economic evaluation of a randomised controlled trial. Mult. Scler. 20, 1123\u20131130 (2014). https:\/\/doi.org\/10.1177\/1352458513515958","journal-title":"Mult. Scler."},{"key":"1471_CR58","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/s0149-2918(03)80100-5","volume":"25","author":"DR Touchette","year":"2003","unstructured":"Touchette, D.R., Durgin, T.L., Wanke, L.A., Goodkin, D.E.: A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin. Ther. 25, 611\u2013634 (2003). https:\/\/doi.org\/10.1016\/s0149-2918(03)80100-5","journal-title":"Clin. Ther."},{"key":"1471_CR59","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jval.2020.10.014","volume":"24","author":"I Aranda-Reneo","year":"2021","unstructured":"Aranda-Reneo, I., Rodr\u00edguez-S\u00e1nchez, B., Pe\u00f1a-Longobardo, L.M., Oliva-Moreno, J., L\u00f3pez-Bastida, J.: Can the consideration of societal costs change the recommendation of economic evaluations in the field of rare diseases? An. Empir. Anal. Value. Health. 24, 431\u2013442 (2021). https:\/\/doi.org\/10.1016\/j.jval.2020.10.014","journal-title":"An. Empir. Anal. Value. Health."},{"key":"1471_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-020-00288-7","author":"JA Duevel","year":"2020","unstructured":"Duevel, J.A., Hasemann, L., Pe\u00f1a-Longobardo, L.M., Rodr\u00edguez-S\u00e1nchez, B., Aranda-Reneo, I., Oliva-Moreno, J., L\u00f3pez-Bastida, J., Greiner, W.: Considering the societal perspective in economic evaluations: A systematic review in the case of depression. Health. Econ. Rev (2020). https:\/\/doi.org\/10.1186\/s13561-020-00288-7","journal-title":"Health. Econ. Rev"},{"key":"1471_CR61","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s10198-019-01087-6","volume":"20","author":"LM Pe\u00f1a-Longobardo","year":"2019","unstructured":"Pe\u00f1a-Longobardo, L.M., Rodr\u00edguez-S\u00e1nchez, B., Oliva-Moreno, J., Aranda-Reneo, I., L\u00f3pez-Bastida, J.: How relevant are social costs in economic evaluations? The case of Alzheimer\u2019s disease. Eur. J. Health. Econ. 20, 1207\u20131236 (2019). https:\/\/doi.org\/10.1007\/s10198-019-01087-6","journal-title":"Eur. J. Health. Econ."},{"key":"1471_CR62","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40273-016-0468-y","volume":"35","author":"J Oliva-Moreno","year":"2017","unstructured":"Oliva-Moreno, J., Trapero-Bertran, M., Pe\u00f1a-Longobardo, L.M., Del Pozo-Rubio, R.: The valuation of informal care in cost-of-illness studies: A systematic review. Pharmacoeconomics 35, 331\u2013345 (2017)","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"1471_CR63","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40273-013-0104-z","volume":"31","author":"RJ Hoefman","year":"2013","unstructured":"Hoefman, R.J., van Exel, J., Brouwer, W.: How to include informal care in economic evaluations. Pharmacoeconomics 31(12), 1105\u201319 (2013)","journal-title":"Pharmacoeconomics"},{"key":"1471_CR64","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2165\/00019053-199813050-00013","volume":"13","author":"N Murphy","year":"1998","unstructured":"Murphy, N., Confavreux, C., Haas, J., K\u00f6nig, N., Roullet, E., Sailer, M., Swash, M., Young, C., M\u00e9rot, J.L.: Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics. 13, 607\u2013622 (1998)","journal-title":"Pharmacoeconomics."},{"key":"1471_CR65","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/PL00007858","volume":"249","author":"MP Amato","year":"2002","unstructured":"Amato, M.P., Battaglia, M.A., Caputo, D., Fattore, G., Gerzeli, S., Pitaro, M., Trojano, M.: The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J. Neurol. 249, 152\u2013163 (2002)","journal-title":"J. Neurol."},{"key":"1471_CR66","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1177\/1352458507077941","volume":"13","author":"P Sobocki","year":"2007","unstructured":"Sobocki, P., Pugliatti, M., Lauer, K., Kobelt, G.: Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult. Scler. 13, 1054\u20131064 (2007). https:\/\/doi.org\/10.1177\/1352458507077941","journal-title":"Mult. Scler."},{"key":"1471_CR67","unstructured":"The Dental and Pharmaceutical Benfits Agency (TLV). General guidelines for economic evaluations from the Dental and Pharmaceutical Benefits Agency. https:\/\/tools.ispor.org\/PEguidelines\/countrydet.asp?c=21&t=1 (2017). Accessed 5 May 2021"},{"key":"1471_CR68","unstructured":"Zorginstituut Nederland. Guideline for economic evaluations in healthcare. Zorginstituut Nederland, Diemen. https:\/\/tools.ispor.org\/PEguidelines\/source\/Netherlands_Guideline_for_economic_evaluations_in_healthcare.pdf (2016). Accessed 15 May 2021"},{"key":"1471_CR69","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). Choices in methods for economic evaluation. Haute Autorit\u00e9 de Sant\u00e9. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-11\/choices_in_methods_for_economic_evaluation_-_2011.pdf (2012). Accessed 15 May 2021"},{"key":"1471_CR70","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/009286150103500122","volume":"35","author":"S Capri","year":"2001","unstructured":"Capri, S., Ceci, A., Terranova, L., Merlo, F., Mantovani, L.: Guidelines for economic evaluations in Italy: Recommendations from the Italian group of pharmacoeconomic studies. Drug. Inf. J. 35, 189\u2013201 (2001)","journal-title":"Drug. Inf. J."},{"key":"1471_CR71","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10198-010-0244-4","volume":"11","author":"J Lopez-Bastida","year":"2010","unstructured":"Lopez-Bastida, J., Oliva, J., Antonanzas, F., Garc\u00eda-Alt\u00e9s, A., Gisbert, R., Mar, J., Puig-Junoy, J.: Spanish recommendations on economic evaluation of health technologies. Eur. J. Health. Econ. 11, 513\u2013520 (2010)","journal-title":"Eur. J. Health. Econ."},{"key":"1471_CR72","unstructured":"Canadian agency for drugs and technologies in health. Guidelines for the Economic evaluation of health technologies: Canada. 4th ed. CADTH https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf (2017) Accessed 15 May 2021"},{"key":"1471_CR73","unstructured":"Behmane, D., Lambot, K., Irs, A., Steikunas, N.: Baltic guideline for economic evaluation of pharmaceuticals (pharmacoeconomic analysis). https:\/\/tools.ispor.org\/PEguidelines\/source\/Baltic-PE-guideline.pdf (2002). Accessed 15 May 2021"},{"key":"1471_CR74","unstructured":"Agency for health technology assessment. Guidelines for conducting health technology assessment (HTA). Agency for health technology assessment https:\/\/tools.ispor.org\/PEguidelines\/source\/Poland_Guidelines-for-Conducting-HTA_English-Version.pdf (2009) Accessed 5 May 2021"},{"key":"1471_CR75","unstructured":"Australian departament of health. Guidelines for preparing submissions to the pharmaceutical benefits advisory commintee (PBAC). Departament of Health https:\/\/pbac.pbs.gov.au (2016) Accessed 15 May 2021"},{"key":"1471_CR76","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1179\/2295333714y.0000000118","volume":"70","author":"M Neyt","year":"2015","unstructured":"Neyt, M., Cleemput, I., Sande, S.V., Thiry, N.: Belgian guidelines for budget impact analyses. Acta. Clin. Belg. 70, 175\u2013180 (2015). https:\/\/doi.org\/10.1179\/2295333714y.0000000118","journal-title":"Acta. Clin. Belg."},{"key":"1471_CR77","unstructured":"National institute for health and care excellence. Guide to methods of technology appraisal 2013. NICE www.nice.org.uk\/process\/pmg9 (2013) Accessed 15 May 2021"},{"key":"1471_CR78","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1524-4733.2005.04010.x","volume":"8","author":"PJ Neumann","year":"2005","unstructured":"Neumann, P.J., Greenberg, D., Olchanski, N.V., Stone, P.W., Rosen, A.B.: Growth and quality of the cost-utility literature, 1976\u20132001. Value. Health. 8, 3\u20139 (2005). https:\/\/doi.org\/10.1111\/j.1524-4733.2005.04010.x","journal-title":"Value. Health."},{"key":"1471_CR79","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/1352458510364632","volume":"16","author":"P Edmonds","year":"2010","unstructured":"Edmonds, P., Hart, S., Gao, W., Vivat, B., Burman, R., Silber, E., Higginson, I.J.: Palliative care for people severely affected by multiple sclerosis: Evaluation of a novel palliative care service. Mult. Scler. J. 16, 627\u2013636 (2010)","journal-title":"Mult. Scler. J."},{"key":"1471_CR80","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3436726","author":"J Martindale-Adams","year":"2020","unstructured":"Martindale-Adams, J., Zuber, J., Levin, M., Burns, R., Graney, M., Nichols, L.O.: Integrating caregiver support into multiple sclerosis care. Multiple. Scler. Int (2020). https:\/\/doi.org\/10.1155\/2020\/3436726","journal-title":"Multiple. Scler. Int"},{"key":"1471_CR81","unstructured":"ASPE (Office of The Assistant Secretary for Planning and Evaluation). National Research Summit on Care, Services and Supports for Persons with Dementia and Their Caregivers: Final Report. U.S. Department of Health and Human Services https:\/\/aspe.hhs.gov\/sites\/default\/files\/migrated_legacy_files\/\/181216\/FinalReport.pdf (2018) Accessed 29 Jan 2022"},{"key":"1471_CR82","doi-asserted-by":"crossref","unstructured":"Schulz, R., Eden, J., Committee on Family Caregiving for Older Adults, Board on Health Care Services, Health and Medicine Division, & National Academies of Sciences, Engineering, and Medicine (eds.): Families Caring for an Aging America. National Academies Press (US), Washington (DC) (2016)","DOI":"10.17226\/23606"},{"key":"1471_CR83","doi-asserted-by":"publisher","DOI":"10.7249\/RR1873","volume-title":"Improving Support for America\u2019s Hidden Heroes: A Military Caregiver Research Blueprint Santa Monica","author":"T Tanielian","year":"2017","unstructured":"Tanielian, T., Bouskill, K.E., Ramchand, R., Friedman, E.M., Trail, T.E., Clague, A.: Improving Support for America\u2019s Hidden Heroes: A Military Caregiver Research Blueprint Santa Monica. CA, USA (2017)"},{"key":"1471_CR84","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown, J.W.L., Coles, A., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Trojano, M., Lugaresi, A., Bergamaschi, R., Grammond, P., Alroughani, R., Hupperts, R., McCombe, P., Van Pesch, V., Sola, P., Ferraro, D., Grand\u2019Maison, F., Terzi, M., Lechner-Scott, J., Flechter, S., Slee, M., Shaygannejad, V., Pucci, E., Granella, F., Jokubaitis, V., Willis, M., Rice, C., Scolding, N., Wilkins, A., Pearson, O.R., Ziemssen, T., Hutchinson, M., Harding, K., Jones, J., McGuigan, C., Butzkueven, H., Kalincik, T., Robertson, N.: Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 321, 175\u2013187 (2019). https:\/\/doi.org\/10.1001\/jama.2018.20588","journal-title":"JAMA"},{"key":"1471_CR85","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/s1474-4422(19)30151-6","volume":"18","author":"D Ontaneda","year":"2019","unstructured":"Ontaneda, D., Tallantyre, E., Kalincik, T., Planchon, S.M., Evangelou, N.: Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet. Neurol. 18, 973\u2013980 (2019). https:\/\/doi.org\/10.1016\/s1474-4422(19)30151-6","journal-title":"Lancet. Neurol."},{"key":"1471_CR86","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12651-017-0231-7","volume":"51","author":"W Eichhorst","year":"2017","unstructured":"Eichhorst, W., Marx, P., Wehner, C.: Labor market reforms in Europe: towards more flexicure labor markets? J. Labour. Market. Res. 51, 3 (2017). https:\/\/doi.org\/10.1186\/s12651-017-0231-7","journal-title":"J. Labour. Market. Res."},{"key":"1471_CR87","unstructured":"Mueller, M., Bourke, E. and Morgan, D.: Assessing the comparability of long-term care spending estimates under the Joint Health Accounts questionnaire. Technical report, OECD. https:\/\/www.oecd.org\/health\/health-systems\/LTC-Spending-Estimates-underthe-Joint-Health-Accounts-Questionnaire.pdf (2020) Accessed 21 Jan 2022"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-022-01471-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-022-01471-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-022-01471-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T09:05:55Z","timestamp":1677920755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-022-01471-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1471"],"URL":"https:\/\/doi.org\/10.1007\/s10198-022-01471-9","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]},"assertion":[{"value":"21 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}